NetworkNewsBreaks – Aerie Pharmaceuticals Inc. (NASDAQ: AERI) Featured in Mizuho Securities Research Report
Aerie Pharmaceuticals Inc. (NASDAQ: AERI) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We applied a weighted average valuation (DCF and EV/Sales) to derive our $34 PT. Our assumptions include: Rhopressa: U.S. peak-sales of $162 mil in 2025. Rocklatan: U.S. peak-sales of $331 mil in 2025. DCF Assumptions: Terminal value of 5x 2028 FCF and a 13% discount rate to derive a $40 PT. EV/Sales Assumptions: 3.8x multiple of 2028 sales, discounted at 13% to derive a $27 PT. In our bull case scenario, we assume greater than anticipated market share…







